


## EGFR-IN-62

<b>Cat. No.:</b>	HY-147862
<b>CAS No.:</b>	2890261-65-9
<b>Molecular Formula:</b>	C <sub>30</sub> H <sub>33</sub> N <sub>9</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	551.64
<b>Target:</b>	EGFR; Apoptosis
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	EGFR-IN-62 (compound 9h) is a potent and reversible EGFR kinase inhibitor, with IC <sub>50</sub> values of 10 nM (L858R/T790 M), 29 nM (WT), and 242 nM (L858R/T790 M/C797S), respectively. EGFR-IN-62 shows antiproliferative activity against A549 and H1975 cell lines, with IC <sub>50</sub> values of 2.53 and 1.56 μM, respectively. EGFR-IN-62 induces dose-dependent apoptosis process, G1/G0-phase arrestation, and the inhibition of motility on A549 and/or H1975 cell lines <sup>[1]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	EGFR <sup>L858R/T790M</sup> 10 ± 1 (IC <sub>50</sub> )	EGFR (WT) 29 ± 2 (IC <sub>50</sub> )	EGFR <sup>L858R/T790M/C797S</sup> 242 ± 9 (IC <sub>50</sub> )

### REFERENCES

[1]. Ding S, et al. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors. Eur J Med Chem. 2022 Aug 5;238:114492.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA